New hope for breast cancer patients – CDK inhibitors
US FDA approval for Abemaciclib (Verzenio) ushers in new hope for breast cancer patients Abemaciclib works by blocking the function of two proteins called cyclin-dependent kinase 4 (CDK4) and CDK6. These proteins play a role in driving cell multiplication, which is key for tumor growth. The approval of abemaciclib in combination with fulvestrant was based…